Pharvaris exec exercises options, sells 4,600 shares

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a scheduled option exercise and share sale on June 25, 2026 under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a scheduled option exercise and share sale on June 25, 2026 under a Rule 10b5-1 trading plan.

She sold 2,300 Pharvaris common shares indirectly through GrayMatters Consulting B.V. and 2,300 shares directly in open‑market transactions at weighted average prices of $35.1242 and $35.1194 per share. The sales were linked to a cashless exercise of stock options for 900 shares at $8.05 and 1,400 shares at $2.59 per share. Following these transactions, Lesage holds 56,450 common shares directly and 131,669 shares indirectly through GrayMatters, while option grants continue to vest over time as disclosed.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider Lesage Anne

Role Chief Early Development

Sold 4,600 shs ($162K)

Approx. gross sale proceeds $162K

Approx. exercise cost $11K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	900	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	1,400	$0.00	$0.00
Exercise	Common Stock	1,400	$2.59	$4K
Exercise	Common Stock	900	$8.05	$7K
Sale	Common Stock	2,300	$35.1194	$81K
Sale	Common Stock	2,300	$35.1242	$81K

Holdings After Transaction: Stock Option (Right to Buy) — 81,172 contracts (Direct); Common Stock — 56,450 shares (Direct); Common Stock — 131,669 shares (Indirect, By GrayMatters Consulting BVBA)

Footnotes (5)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage
4. F4. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
5. F5. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold indirectly: 2,300 shares at $35.1242 Shares sold directly: 2,300 shares at $35.1194 Options exercised (strike $8.05): 900 shares at $8.05 +5 more

8 metrics

Shares sold indirectly 2,300 shares at $35.1242 Common stock sold via GrayMatters on June 25, 2026

Shares sold directly 2,300 shares at $35.1194 Common stock sold directly on June 25, 2026

Options exercised (strike $8.05) 900 shares at $8.05 Common stock acquired via option exercise

Options exercised (strike $2.59) 1,400 shares at $2.59 Common stock acquired via option exercise

Direct common shares after 56,450 shares Direct Pharvaris common stock holdings post-transaction

Indirect common shares after 131,669 shares Indirect Pharvaris holdings via GrayMatters after sale

Remaining options (strike $2.59) 7,072 stock options Options expiring on January 1, 2030

Remaining options (strike $8.05) 74,100 stock options Options expiring on April 6, 2033

Key Terms

Rule 10b5-1 trading plan, cashless exercise transaction, weighted average sale price, Stock Option (Right to Buy), +1 more

5 terms

Rule 10b5-1 trading plan financial

"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

cashless exercise transaction financial

"shares were sold in connection with the exercise of stock options in a cashless exercise transaction"

weighted average sale price financial

"reported price represents a weighted average sale price for shares sold in multiple transactions"

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

vesting in 1/48 monthly installments financial

"remaining shares vesting in 1/48 monthly installments thereafter"

FAQ

What insider transactions did Pharvaris (PHVS) executive Anne Lesage report?

Anne Lesage reported a scheduled option exercise and share sale on June 25, 2026. She exercised stock options and sold 4,600 Pharvaris common shares in open‑market trades linked to a pre‑arranged Rule 10b5‑1 trading plan and cashless exercise structure.

How many Pharvaris (PHVS) shares did Anne Lesage sell and at what prices?

She sold 4,600 Pharvaris common shares in total, split into two 2,300‑share blocks. The weighted average sale prices were approximately $35.1242 per share for indirect holdings and $35.1194 per share for direct holdings, executed in multiple transactions that day.

Were Anne Lesage’s Pharvaris (PHVS) trades made under a Rule 10b5-1 trading plan?

Yes. Footnotes state the exercise and related sales were scheduled under a Rule 10b5‑1 trading plan. Such plans are pre‑arranged trading programs that allow insiders to systematically sell shares over time, reducing the significance of trade timing as an information signal.

What stock options did Anne Lesage exercise in this Pharvaris (PHVS) Form 4?

She exercised options for 900 Pharvaris shares at a strike price of $8.05 and 1,400 shares at $2.59. The filing notes these options vest over time in monthly installments following initial 25% vesting dates in 2021 and 2024, respectively.

What are Anne Lesage’s Pharvaris (PHVS) holdings after the reported transactions?

After the June 25, 2026 transactions, Anne Lesage holds 56,450 Pharvaris common shares directly and 131,669 shares indirectly via GrayMatters Consulting B.V. These figures reflect her remaining equity stake following the option exercises and associated open‑market sales disclosed.

How are Anne Lesage’s indirect Pharvaris (PHVS) holdings structured?

Her indirect Pharvaris holdings are reported as being held by GrayMatters Consulting B.V. A footnote explains this entity is controlled by Dr. Lesage, so transactions attributed to GrayMatters represent activity in an entity associated with her, rather than only personal direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lesage Anne

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Early Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		M(1)		1,400	A	$2.59	57,850	D
Common Stock	06/25/2026		M(1)		900	A	$8.05	58,750	D
Common Stock	06/25/2026		S(1)		2,300	D	$35.1194(2)	56,450	D
Common Stock	06/25/2026		S(1)		2,300	D	$35.1242(2)	131,669	I	By GrayMatters Consulting BVBA(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.05	06/25/2026		M(1)			900	(4)	04/06/2033	Common Stock	900	$0	74,100	D
Stock Option (Right to Buy)	$2.59	06/25/2026		M(1)			1,400	(5)	01/01/2030	Common Stock	1,400	$0	7,072	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $35.00 to $35.30. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

4. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)